In order to study the post-authorization adverse reactions (AEs) of the COVID-19 vaccines currently authorized in Morocco, they were reported to the pharmacovigilance unit after the vaccination of health personnel at the Ibn Sina University Hospital Center in Rabat, Morocco, with the Covishield recombinant vaccine from AstraZeneca or the inactivated SARS-CoV-2 (Vero Cell) vaccine from Sinopharm. The objective is to study the adverse effects reported after vaccination with two vaccines against COVID-19. This study was conducted as a retrospective review, using the VigiFlow system and Medical Dictionary for Regulatory Activities (MedDRA) as a classification tool. The overall incidence of local and systemic adverse events in this study was 7.55%. It was observed that the nervous system was the most frequently affected organ by the Covishield vaccine and the inactivated Vero Cell vaccine (46.26% and 42.22%, respectively). These effects were mainly dizziness (57.64% and 47.36%), followed by headache (21.39% and 15.78%) and vagal reactions (5.24% and 23.68%). The second most reported class of AEs includes general disorders and infection of the injection site (29.49% and 18.88%). In this class we mainly find pain at the injection site (65.75% and 52.94%), influenza-like illness and malaise (5.47% and 11.76%). Finally, other classes of conditions have been notified, but with low incidences. A comparison of the AE profiles of the two vaccines revealed an overall similarity in AEs. Until the date of this work, exploration of the data has revealed no cases of death, no cases of thrombosis, or of allergic reaction.